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Abstract
Background Sarcopenia, characterized by low muscle mass, associates with mortality in patients with cirrhosis. Skeletal
muscle area in a single computed tomography image at the level of the third lumbar vertebrate (L3) is a valid representative
of whole body muscle mass. Controversy remains regarding applicability of psoas muscle to identify patients at greater risk of
mortality. We aimed to determine psoas muscle index (PMI) association with skeletal muscle index (SMI) and to evaluate the
capacity of PMI to predict liver transplant waitlist mortality.
Methods We evaluated listed adult patients with cirrhosis from 2012 to 2013 at four North American liver transplant cen-
tres. From L3 computed tomography images within 3 months of listing, we determined SMI and PMI expressed by cm2/m2.
Low SMI was defined as SMI <39 cm2/m2 in women and <50 cm2/m2 in men as published by us earlier. Cut-offs for PMI
to predict mortality were established using a receiver-operating characteristic analysis. Mortality predictors were determined
using competing-risk analysis with reported results as subdistribution hazard ratios (sHRs).
Results Of 353 waitlist candidates, 68% were men, mean age 56 ± 9 years, and Model for End-stage Liver Disease of 16 ± 8
points. Low SMI was present more frequently in men than women (51 vs. 36%, P = 0.02). Moderately strong correlation
between SMI and PMI was observed (r > 0.7, P < 0.001). Low PMI (males < 5.1 cm2/m2; females < 4.3 cm2/m2) yielded poor
and moderate concordance with low SMI in men and women, respectively (Kappa coefficient 0.31 and 0.63). SMI (39 ± 9 vs.
43 ± 7 cm2/m2; P = 0.009) and PMI (4.4 ± 1.3 vs. 5.2 ± 1.1 cm2/m2; P = 0.001) were lower in women who died and/or were
delisted (compared with non-deceased patients) whereas men who died and/or were delisted had only lower SMI (47 ± 7
vs. 51 ± 9 cm2/m2; P = 0.003), but not PMI compared with non-deceased patients. In women, both SMI (sHR 0.94,
P = 0.048) and PMI (sHR 0.58, P = 0.002) were predictors of mortality, while in men, SMI was significant (sHR 0.95,
P = 0.001) and PMI showed a trend to be (sHR 0.85, P = 0.09) associated with mortality. Overall, 104 patients (29%) were
misclassified between SMI and PMI categories. Using PMI cut-offs, 66% and 28% of low SMI men and women, who have a
higher risk of mortality, were incorrectly classified as low risk.
Conclusions Skeletal muscle index is a more complete and robust measurement than PMI, especially in men with cirrhosis.
Low PMI identifies an incomplete subset of patients at increased risk of mortality indicated by low SMI. Given the poor
performance of PMI, SMI should not be substituted by PMI.
Keywords Sarcopenia; Prognosis; Computed tomography; End-stage liver disease
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Introduction
Sarcopenia, characterized by low muscle mass, is indepen-
dently associated with elevated mortality in end-stage liver
disease (ESLD) patients.1–4 Higher waitlist mortality and
longer hospital stay following liver transplantation (LT) have
been reported in patients with ESLD and sarcopenia.5 In most
studies, sarcopenia was more prevalent in male patients with
cirrhosis compared with female patients.1,5,6
Various approaches to assess body composition such as
body mass index (BMI, kg/m2), bioelectrical impedance
analysis, and dual-energy X-ray absorptiometry6,7 have been
used to patients with cirrhosis. Non-invasive imaging with
computed tomography (CT) has been applied as a precise
technique for muscle and adipose tissue quantification.8
Diagnostic CT imaging is a routine part of LT assessment in
most LT centres, to screen for hepatocellular carcinoma
(HCC) and evaluate the vascular and biliary anatomy.
A comprehensive definition of sarcopenia has been
recently developed in a population of cirrhotic patients listed
for LT at four North American LT centres.1 CT-determined
skeletal muscle index (SMI) was used to discriminate waitlist
mortality in these patients.1 SMI in a single CT image at the
level of the third lumbar vertebrate (L3) is a reliable and valid
representative of whole body muscle mass.8,9 Besides
SMI, individual muscle measurements, i.e. psoas muscle
thickness,10 psoas muscle index (PMI),11 and psoas muscle
cross-sectional area (PMA),12,13 have been used as indicators
of increased risk of mortality in later literature. Psoas muscle
assessment is easy and rapid,11 and not influenced by abdom-
inal swelling,10 but is affected by long-term chronic disease.12
Controversy remains regarding the use of PMI instead of SMI
for the purposes of mortality risk prediction. We therefore
first determined PMI association with SMI as continuous
and dichotomous variables in patients with ESLD. Second,
we evaluated the capability of PMI to predict mortality in
patients with ESLD awaiting LT.
Methods
Study population
Included were adult (≥18 years) patients with cirrhosis newly
listed for LT (n = 353) from 1 January through 31 December
2012 at four North American LT centres: (i) University of
California, San Francisco (141); (ii) University of Pittsburgh
(n = 83); (iii) Mayo Clinic in Arizona (n = 52); and (iv) Univer-
sity of Alberta (77). Patients with an abdominal CT scan
within 3 months of listing were included. All four centres
are part of the Fitness, Life Enhancement, and Exercise in
Transplantation (FLEXIT) Consortium with the ultimate goal
to better understand muscle abnormalities, frailty, and their
association with outcome in patients listed for LT. The study
protocol was reviewed and approved by the institutional
research ethics board at each centre. Clinical and demo-
graphic characteristics of the patients were collected from
the medical charts at each centre. Coded, de-identified
clinical data and CT images were shared among consortium
members under the terms of a formal data use agreement
among the institutions.
Computed tomography image analysis
Skeletal muscle areas were quantified analysing L3-CT scans
by Slice-O-Matic software (V4.2; Tomovision, Montreal, QC,
Canada) or Advantage Windows 2.2 Volume Viewer (GE
Healthcare, Waukesha, WI), depending on the centre.1
Two collaborators blinded to patient outcome read the CT
images. Correlation (r) between areas measured by two
independent observers was 0.98 for both psoas and total
skeletal muscle. Standard Hounsfield Unit thresholds of 29
to 15014 were used to estimate muscle cross-sectional areas.
By applying tissue-specific radiodensity, muscle area assess-
ments were not affected by ascites. Muscles visualized at L3
include the psoas, erector spinae, quadratus lumborum,
transversus abdominis, external and internal obliques, and
rectus abdominis. Cross-sectional areas of these muscles were
calculated by summing tissue pixels followed bymultiplying by
the pixel surface areas. Total abdominal muscle area was
quantified using semi-automatic measurement of all these
muscle areas. For psoas evaluation, bilateral psoasmuscle area
was quantified. From L3-CT images, we determined two mus-
cularity variables: total skeletal muscle cross-sectional area
to establish the SMI, and psoas muscle area to determine the
PMI, each normalized to the squared patient height (cm2/m2).
Statistical analysis
Continuous variables are reported as mean and standard
deviation, and independent t-test was used to compare
means of two independent groups. Descriptive statistics for
categorical variables are presented as frequency and percent-
ages, and Pearson χ2 test was conducted to compare study
groups. Correlation between SMI and PMI was evaluated
using Pearson’s correlation coefficient (r) analysis. C-statistics
analysis was used to evaluate the performance of muscle
cross-sectional area, SMI, PMA, and PMI for waitlist mortality
prediction.
The primary outcome of the study was waitlist mortality,
described as death or delisting for being too sick for LT. In
patients listed for LT, death and LT, the two competing out-
comes of interest, were evaluated using competing-risk
analysis.15 Significant predictors of mortality in patients listed
for LT were determined using univariate and multivariate
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Fine and Gray subdistribution hazards models, and the results
were reported as subdistribution hazard ratios (sHRs) with
95% confidence intervals (CI). Variables with the P < 0.10
in the univariate analysis were included in the multivariate
model.
Cut-offs for PMI to predict mortality were established
using a receiver-operating characteristic analysis. Model
ability to differentiate between outcome groups was
assessed using the area under the curve. Sex-specific
potential cut-offs with the highest Youden’s Index (sensitivity
+ specificity 1) were included in adjusted competing risk
models, and the value with a highest significant P-value was
considered as the optimal cut-off point. Low SMI was defined
using pre-established mortality-associated cut-offs in ESLD
patients waiting for LT as SMI <39 cm2/m2 in women and
<50 cm2/m2 in men.1 Potential cut-offs for SMI in Carey
et al.1 was calculated based on a log-rank and Wilcoxon
test statistics, followed by combination of maximized power
and a significant P-value. It was mentioned by previous
researchers15,16 that methods for the estimation of area
under the receiver-operating characteristic curve are primar-
ily based on the Wilcoxon rank-sum test and this relationship
could offer a preferred level of statistical power (low type II
error) in comparative experiments.
Overall survival estimates, 6 month, 1 year, and 2 year
survival probabilities were obtained using Kaplan–Meier
curves, and comparison between low and high PMI patients
was conducted using the log-rank test. The Cohen’s kappa
coefficient was applied to obtain agreement between SMI
and PMI categories.
Results
Characteristics of listed patients
Characteristics of patients with cirrhosis listed for LT are
presented in Table 1. Of 353 waitlist candidates, 70% were
male with the mean age of 56 ± 9 years and Model for
End-stage Liver Disease (MELD) score of 16 ± 8 points. Mean
BMI was 28 ± 6 kg/m2 with the majority (67%) of the patients
being overweight or obese (BMI ≥ 25). Concomitant HCC was
present in 41% of patients. Patients were followed to death
(101), LT (170), or censoring (82).
Overall mean SMI was 47 ± 9 cm2/m2 (range 23–81), and
PMI was 6 ± 1.7 cm2/m2 (range 2–12). Despite similar BMI
between men and women, SMI (50 ± 8 vs. 42 ± 8 cm2/m2)
and PMI (6.5 ± 1.6 vs. 4.9 ± 1.3 cm2/m2) were higher in
men (P < 0.001 for each; Table 1). Low SMI was more
frequent in men compared with women (51 vs. 36%;
P = 0.02). SMI (39 ± 9 vs. 43 ± 7 cm2/m2; P = 0.009) and
PMI (4.4 ± 1.3 vs. 5.2 ± 1.1 cm2/m2; P = 0.001) were lower
in women who died and/or were delisted (compared with
non-deceased patients) whereas men who died and/or were
delisted had only lower SMI (47 ± 7 vs. 51 ± 9 cm2/m2;
P = 0.003), but not PMI compared with non-deceased
patients (Table 2). Higher proportion of the patients who died
and/or were delisted had HCC at the time of listing (50% vs.
36%; P = 0.02). Considering differences in SMI and PMI
between men and women, mortality analysis was conducted
by sex.
Figure 1 highlights the total skeletal muscle and
psoas muscle quantification at L3 from two male patients.
Figure 1A,B presents a patient who had low SMI (40 cm2/m2)
but high PMI (6.6 cm2/m2). Figure 1C,D shows a patient
with high SMI (54 cm2/m2) but low PMI (4.8 cm2/m2). This
example illustrates that psoas muscle quantification may not
necessarily reflect total muscle area assessment.
Association between skeletal muscle index, psoas
muscle index, and waitlist mortality
There was a significant linear (P < 0.001) and moderately
strong (r = 0.73) relationship between SMI and PMI in male
Table 1 Patient clinical characteristics by sex at the time of listing
Characteristics
All Patients
(n = 353)
Male
(n = 246)
Female
(n = 107) P value
Age (years) 56 ± 9 56 ± 9 56 ± 9 0.74
Albumin
(g/dL, 3.5–5.5)
3 ± 2 3 ± 1 3 ± 3 0.12
Sodium
(mmol/L, 133–146)
135 ± 5 134 ± 5 134 ± 6 0.35
MELD score 16 ± 8 16 ± 8 17 ± 9 0.29
Hepatic encephalopathy 0.73
None 157 (48) 112 (49) 45 (45)
Well controlled 156 (48) 105 (46) 51 (51)
Poorly
controlled
14 (4) 10 (4) 4 (4)
Ascites 0.04
None 131 (40) 98 (43) 33 (33)
Mild 130 (40) 80 (35) 50 (50)
Refractory 66 (20) 49 (22) 17 (17)
HCC 144 (41) 111 (44) 33 (30) 0.02
Body composition characteristics
BMI (kg/m2) 28 ± 6 28 ± 5 27 ± 6 0.19
PMA (cm2) 18 ± 6 20 ± 5 13 ± 3 <0.001
PMI (cm2/m2) 6 ± 1.7 6.5 ± 1.6 4.9 ± 1.3 <0.001
SMA (cm2) 129 ± 31 154 ± 27 109 ± 22 <0.001
SMI (cm2/m2) 47 ± 9 50 ± 8 42 ± 8 <0.001
VATI 35 ± 27 37 ± 28 29 ± 23 0.009
SATI 60 ± 40 57 ± 37 69 ± 44 0.004
Muscle
attenuation (HU)
36 ± 9 37 ± 9 33 ± 9 <0.001
Low SMIa 165 (47) 126 (51) 39 (36) 0.02
Numbers in parentheses are percentages.
BMI, body mass index; HCC, hepatocellular carcinoma; MELD,
Model for End-stage Liver Disease; PMA, psoas muscle area; PMI,
psoas muscle index; SATI, subcutaneous adipose tissue index;
SMA, skeletal muscle area; SMI, skeletal muscle index; VATI, visceral
adipose tissue index.
aLow SMI was defined using established cut-offs in patients with
cirrhosis listed for LT.1
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patients (Figure 2A). Waitlist mortality prediction yielded a C-
statistic of 0.62 (95% CI 0.55–0.70, P = 0.004) for SMI and
0.56 (95% CI 0.48–0.65, P = 0.13) for PMI. The same results
were obtained using areas rather than indices to predict
waitlist mortality, again with a limited ability for psoas to pre-
dict mortality (Table 3). However, indices were selected as
the standardized muscle values.1,17
In univariate analysis, assessing the association between
clinical parameters and outcome, SMI, as a continuous
variable, was significantly associated with waitlist mortality
(sHR 0.96, 95% CI 0.93–0.98, P < 0.001; Table 4A). Consid-
ering LT as the competing event, SMI was independently
associated with mortality after adjusting for MELD score
and HCC (sHR 0.95, 95% CI 0.92–0.98, P = 0.001;
SMI-Model, Table 4A). Using pre-established mortality-
associated cut-offs for SMI, male patients with low SMI,
as a categorical variable, had more than two-fold higher
mortality risk after adjusting for recognized mortality
predictors (sHR 2.46, 95% CI 1.38–4.39, P = 0.002;
SMI-Model, Table 5A).
Psoas muscle index (cm2/m2), as a continuous variable,
demonstrated a trend towards negative association with
mortality in both univariate (sHR 0.86, 95% CI 0.73–1.02,
P = 0.08) and multivariate models (sHR 0.85, 95% CI 0.70–
1.03, P = 0.09; Table 4A). Every 1 cm2/m2 increase in PMI
tended to be associated with 15% decreased risk of death.
Applying the highest Youden’s Index, PMI of 5.1 cm2/m2
was found to be independently associated with
mortality with a sensitivity of 84%. Male patients with PMI
<5.1 cm2/m2 had a two times higher risk of mortality
(HR 2.04, 95% CI 1.13–3.68, P = 0.02; PMI-Model, Table 5A)
compared with the patients with high PMI (≥5.1 cm2/m2).
The 6 month, 1 year, and 2 year probabilities of survival were
80%, 59%, and 54% in patients with low PMI compared with
88%, 83%, and 68% in men with high PMI (log rank = 0.02)
(Figure 3A).
We observed a moderately strong (r = 0.76) linear
(P < 0.001) correlation between SMI and PMI in female pa-
tients (Figure 2B). The ability of the SMI and PMI to rank pa-
tients according to waitlist mortality (i.e. C-statistic) were
0.66 (95% CI 0.55–0.77, P = 0.007) and 0.68 (95% CI 0.57–
0.79, P = 0.002), respectively (Table 3).
Univariate and multivariate competing risk analysis of
features associated with mortality were conducted in fe-
male patients listed for LT. Albumin, MELD score, SMI,
and PMI were predictors of mortality in women in the
univariate analysis (Table 4B). There was a negative associ-
ation between SMI (cm2/m2) and mortality in multivariate
models (sHR 0.94, 95% CI 0.89–1.00, P = 0.048). PMI
(cm2/m2) was significantly negatively associated with mor-
tality in multivariate models (sHR 0.58, 95% CI 0.41–0.82,
P = 0.002) (Table 4B). In a multivariate model including
confounding clinical variables, low SMI increased by
two-fold the risk of mortality in female patients (sHR
2.05, 95% CI 1.00–4.21, P = 0.05; SMI-Model, Table 5B)
compared with patients with high SMI. In women, PMI of
4.3 cm2/m2 was found to yield the highest Youden’s Index,
with the sensitivity of 78% and area under the curve of
0.68 (95% CI 0.57–0.79). Low PMI (PMI <4.3 cm2/m2)
was an independent predictor of elevated mortality
(sHR 2.47, 95% CI 1.24–4.95, P = 0.01), after adjusting
for other survival predictors (PMI-Model, Table 5B).
Kaplan–Meier analysis to calculate survival probability
based on psoas muscle cut-offs revealed that the 6 month,
1 year, and 2 year probabilities of survival were 63%, 47%,
and 34% in patients with low PMI compared with 85%,
75%, and 62% in women with high PMI (log rank = 0.002)
(Figure 3B).
Concordance between skeletal muscle index and
psoas muscle index categories
Of all male patients with low SMI, only 34% were categorized
as low based on the PMI (Table 6). The Kappa coefficient for
the agreement between low SMI and low PMI was 0.31
(P < 0.001; Table 6), demonstrating a poor agreement
between the two assessments. In women, 72% of those
classified as low SMI were classified in low PMI group. The
Table 2 Clinical characteristics of listed patients according to the mortal-
ity status
Characteristics
Died/Delisted
(n = 101)
All others
(n = 252) P value
Age (years) 57 ± 9 55 ± 9 0.18
Albumin
(g/dL, 3.5–5.5)
3 ± 3 3 ± 1 0.53
Sodium
(mmol/L, 133–146)
134 ± 5 135 ± 6 0.30
MELD score 17 ± 8 16 ± 9 0.38
Hepatic encephalopathy 0.74
None 48 (50) 107 (47)
Well controlled 43 (45) 111 (49)
Poorly
controlled
5 (5) 9 (4)
Ascites 0.69
None 35 (36) 94 (42)
Mild 41 (43) 87 (38)
Refractory 20 (21) 46 (20)
HCC 50 (50) 91 (36) 0.02
Body composition characteristics
BMI (kg/m2) 27 ± 6 28 ± 5 0.07
PMI (cm2/m2) 5.5 ± 1.7 6.2 ± 1.6 <0.001
SMI (cm2/m2) 44 ± 9 49 ± 9 <0.001
Males
PMI (cm2/m2) 6.2 ± 1.6 6.6 ± 1.6 0.12
SMI (cm2/m2) 47 ± 7 51 ± 9 0.003
Females
PMI (cm2/m2) 4.4 ± 1.3 5.2 ± 1.1 0.001
SMI (cm2/m2) 39 ± 9 43 ± 7 0.009
Numbers in parentheses are percentages.
BMI, body mass index; HCC, hepatocellular carcinoma; MELD,
Model for End-stage Liver Disease; PMI, psoas muscle index; SMI,
skeletal muscle index.
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agreement estimated by the Kappa coefficient was 0.63 in
women indicating a moderate agreement between the two
assessments. Overall, 104 patients (29%) were misclassified
between SMI and PMI categories (Table 6). No significant
difference regarding age (56 ± 9 vs. 55 ± 10; P = 0.42), HCC
(34% vs. 41%, P = 0.19), ascites (62% vs. 59%, P = 0.13),
and albumin (3 ± 2 vs. 3 ± 1 g/dL; P = 0.65) was observed
between a misclassified group of patients and those who
were correctly classified. Male patients were more likely
to be misclassified (35% vs. 17%, P = 0.001), and MELD
score was lower in misclassified patients (16 ± 7 vs.
18 ± 10 cm2/m2; P = 0.03).
Discussion
The prevalence of sarcopenia, defined as low SMI, in cirrhosis
ranges between 22% and 70% according to CT studies,18 with
higher prevalence in men.4,6 SMI has been shown to be a
reliable indicator of total body muscle mass,8,9 and predictor
of mortality in patients with cirrhosis,4,6 and in patients listed
for LT.1 Currently, there is a discrepancy in the literature
regarding sarcopenia quantification and definition in cirrho-
sis. This demonstrates the necessity to develop a standard-
ized definition of sarcopenia that can be implemented in
other LT centres. The authors have started a consortium of
LT centres to develop a comprehensive data set and reach
consensus to perform the muscularity assessment in a
uniform fashion. To date, this data set is the only North
American study to define sarcopenia using data derived from
a diverse population of LT candidates, which has been
implemented in this study.
Sarcopenia associates with various clinical complications in
aging19–22 and cachexia-associated chronic diseases3,23–26;
therefore, sensitive and reproducible measures of muscle
mass are required to assess the evolution of muscle loss
and to follow outcomes of therapeutic interventions26,27
directed at attenuation of tissue loss in order to improve
outcome of patients. Considering availability of diagnostic
Figure 1 Abdominal computed tomography images taken at the third lumbar vertebra of two male patients with cirrhosis applied to quantify total
muscle and psoas muscle areas. Panels (A) and (B) present a patient who had low skeletal muscle index (SMI) (40 cm2/m2) but high psoas muscle index
(PMI) (6.6 cm2/m2). Panels (C) and (D) show a patient with high SMI (54 cm2/m2) and low PMI (4.8 cm2/m2).
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CT scans in the majority of cachexia-associated disease such
as cancer and cirrhosis, as well as high accuracy and time
efficacy of different software programmers28 for body
composition measurements, finding an appropriate indicator
of muscle mass, i.e. total muscle or psoas, should be the
priority in cachexia context.
This study aimed to investigate whether low PMI can be
applied as a representative surrogate of low SMI for
predicting waitlist mortality in patients with cirrhosis. A
moderately strong correlation between SMI and PMI as
continuous variables was observed; however, categorizing
PMI yielded poor and moderate concordance with SMI in
men and women, respectively. Our data show that PMI has
a poor capacity to identify patients with higher waitlist
mortality in cirrhosis. A significant proportion of patients with
higher waitlist mortality risk might be underestimated in men
using PMI cut-offs, as more than half of men with low SMI
(66%) were categorized as having high PMI with an
implied lower mortality risk. Poor agreement (Kappa coeffi-
cient = 0.31) between the two assessments accounted for
the different proportions of patients in each category.
Moreover, among men, the cut-off for SMI values identified
a 51% of participants into the low muscle mass group.
Conversely, the threshold that was identified as most statisti-
cally optimal for PMI only classifies 19% of the men as low
muscle, which is a large discrepancy, and results are in poor
concordance. Moreover, it is not only the selected PMI
cut-offs that perform poorly, but also when PMI was evalu-
ated as a continuous variable in relation to mortality risk
and the mean of died/delisted group was compared with all
others, it was not as effective as SMI in men. As a conse-
quence, it is not only the stratification strategy used that is
flawed but also that analysis of PMI is not as good a metric
as SMI, in men. Therefore, patients with a higher risk of
mortality would incorrectly be classified as low risk and given
the importance of sarcopenia in predicting mortality of men
with cirrhosis; PMI should not be used to substitute SMI to
predict mortality. Greater predictive accuracy and robustness
of SMI compared with that of PMI appears to be biologically
plausible because SMI takes into account a larger proportion
of total muscle mass than does PMI.
Although sarcopenia is not a current criterion for expe-
dited LT, giving some priority to those patients with
sarcopenia may help to decrease mortality in a subgroup of
patients with cirrhosis.3,29 Sarcopenia is one of the major
manifestations of protein-energy malnutrition in cachexia-
associated diseases, and to prevent adverse clinical implica-
tions, early and proper identification of patients with
sarcopenia should be implanted and intense nutritional and
physical interventions should be included to improve patient
conditions and to lessen mortality risk in patients with higher
risk as determined by low SMI.
In women, the cut-off for PMI-associated mortality was at
the 33rd percentile of calculated PMI, and subsequently, 33%
Figure 2 Scatter graph depicting correlations between skeletal muscle
index and psoas muscle index in (A) male and (B) female patients. Using
Pearson’s correlation coefficient, moderately strong association between
psoas muscle index (PMI) and skeletal muscle index (SMI) was observed
in men (r = 0.73) and women (r = 0.76).
A
B
Table 3 Discriminatory value of different muscle measurements in
predicting waitlist mortality
Variable AUC 95% CI P value
Men
PMA 0.56 0.48–0.65 0.15
PMI 0.56 0.48–0.65 0.13
SMA 0.64 0.56–0.71 0.002
SMI 0.62 0.55–0.70 0.004
Women
PMA 0.67 0.56–0.78 0.004
PMI 0.68 0.57–0.79 0.002
SMA 0.65 0.53–0.76 0.01
SMI 0.66 0.55–0.77 0.007
AUC, area under the ROC curve; CI, confidence interval; PMA, psoas
muscle area; PMI, psoas muscle index; SMA, skeletal muscle area;
SMI, skeletal muscle index.
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of women fell into the high-risk group. This result is similar to
33% of women with low SMI, below the established cut-off
previously reported by our group.1 Although Kappa coeffi-
cient showed good agreement between two assessments in
women (0.63), there might still be some misclassification as
28% of women with low SMI and higher mortality risks were
placed in the high-PMI category. We speculate that psoas
muscle in women with cirrhosis is preferentially depleted in
sarcopenia, whereas muscles other than psoas might be
affected at greater intensity in men. The exact mechanism
behind this association has not been elucidated. However, a
study in post-menopausal women enrolled in a weight loss
training programme showed that muscle was mainly lost
from psoas and erector spine areas but not from lateral
abdominal area and rectus abdominis.30 Moreover, it has
been described by other researchers that noticeable decline
in female psoas muscle area may be due to post-menopausal
hormonal changes.31 This emphasizes the necessity for
longitudinal studies to investigate potential loss of PMI and
SMI stratified by sex.
Table 4 Clinical parameters associated with mortality in listed patients according to sex
Univariate analysis
Multivariate analysis
SMI-Model PMI-Model
Characteristic sHR (95% CI) P value sHR (95% CI) P value sHR (95% CI) P value
A. Male Patients
Age (years) 1.02 (0.99–1.06) 0.21
Albumin (g/dL) 0.80 (0.51–1.25) 0.32
MELD score 1.01 (0.98–1.04) 0.45 1.01 (0.98–1.05) 0.52 1.02 (0.98–1.05) 0.32
Ascites 1.22 (0.87–1.70) 0.25
Sodium (mmol/L) 0.97 (0.93–1.01) 0.13
HCC 1.76 (1.07–2.90) 0.03 2.16 (1.19–3.91) 0.01 1.93 (1.08–3.44) 0.03
Hepatic encephalopathy 1.05 (0.67–1.65) 0.82
SMI (cm2/m2) 0.96 (0.93–0.98) <0.001 0.95 (0.92–0.98) 0.001
PMI (cm2/m2) 0.86 (0.73–1.02) 0.08 0.85 (0.70–1.03) 0.09
B. Female patients
Age (years) 1.01 (0.98–1.05) 0.55
Albumin (g/L) 1.02 (0.997–1.05) 0.07 0.74 (0.42–1.31) 0.30 0.75 (0.44–1.27) 0.29
MELD score 1.02 (0.99–1.05) 0.25 1.00 (0.97–1.04) 0.69 1.00 (0.97–1.04) 0.73
Ascites 0.90 (0.63–1.30) 0.59
Sodium (mmol/L) 0.99 (0.95–1.04) 0.82
HCC 1.45 (0.80–2.65) 0.22
Hepatic encephalopathy 0.93 (0.51–1.68) 0.80
SMI (cm2/m2) 0.94 (0.90–0.99) 0.01 0.94 (0.89–1.00) 0.048
PMI (cm2/m2) 0.59 (0.44–0.79) <0.001 0.58 (0.41–0.82) 0.002
sHRs and P values were estimated using Fine-Gray subdistribution hazard model.
CI, confidence interval; HCC, hepatocellular carcinoma; MELD, Model for End-stage Liver Disease; PMI, psoas muscle index; sHR,
subdistribution hazard ratio; SMI, skeletal muscle index.
Table 5 Association of low SMI and low PMI with mortality in listed patients according to sex
Univariate analysis
Multivariate analysis
SMI-Model PMI-Model
Characteristic sHR (95% CI) P value sHR (95% CI) P value sHR (95% CI) P value
A. Male patients
MELD score 1.01 (0.98–1.04) 0.45 1.02 (0.99–1.06) 0.22 1.02 (0.99–1.05) 0.26
HCC 1.76 (1.07–2.90) 0.03 2.18 (1.22–3.89) 0.008 1.98 (1.12–3.49) 0.02
Low SMIa 2.17 (1.29–3.66) 0.003 2.46 (1.38–4.39) 0.002
Low PMIb 1.85 (1.05–3.24) 0.03 2.04 (1.13–3.68) 0.02
B. Female patients
MELD score 1.02 (0.99–1.05) 0.25 1.00 (0.97–1.04) 0.82 1.01 (0.98–1.05) 0.47
Albumin (g/dL) 1.02 (0.997–1.05) 0.07 0.79 (0.44–1.41) 0.42 0.77 (0.43–1.36) 0.36
Low SMIa 2.12 (1.14–3.93) 0.02 2.05 (1.00–4.21) 0.050
Low PMIb 2.45 (1.32–4.58) 0.005 2.47 (1.24–4.95) 0.01
sHRs and P values were estimated using Fine-Gray subdistribution hazard model.
Variables with a P < 0.10 of Table 2 are included in multivariable model.
CI, confidence interval; MELD, Model for End-stage Liver Disease; PMI, psoas muscle index; sHR, subdistribution hazard ratio; SMI, skeletal
muscle index.
aLow SMI was defined using established cut-offs in patients with cirrhosis.1
bDefined as PMI < 5.1 cm2/m2 in men and PMI < 4.3 cm2/m2 in women.
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The psoas is a key muscle for posture and core strength,32
which might represent sarcopenia better than other individual
anthropometric muscle measurements, such as triceps
thickness;17 however, it only accounts for approximately 13%
of total skeletal muscle area at the level of L3 in our
population. Psoas muscle mass in an individual patient might
also be affected by other conditions such as degenerative
spine disease and chronic low back pain,33 both common
conditions in an older population and potentially selective
for psoasmuscle loss compared with loss of total musculature.
Studies evaluating the association between psoas muscle
and mortality in various populations have yielded inconsis-
tent results.10–12,34,35 Discrepancy may arise because of
disparate techniques and measurements of psoas muscle,
such as PMA, PMI (normalized to patient squared height),11
right psoas thickness at the level of umbilicus,10 short-axis
to long-axis ratios of the right and left psoas muscles36 that
have been applied to predict clinical outcomes. Because of
the asymmetrical shape of psoas muscle, validity and reliabil-
ity of some of those approaches could be questioned.37
Despite a strong association between sarcopenia, measured
by total psoas area, with post-transplant mortality, variations
in total psoas areas in patients undergoing LT led to extreme
variation in mortality risk following LT.12
Overall, data regarding the use of PMI instead of SMI for
the purposes of mortality risk prediction in cirrhosis are
limited. Among various muscle measurements, i.e. PMA,
PMI, and SMI at L3, to predict post-LT mortality in 256
transplanted patients, PMA was selected as the simplest
measure with the highest accuracy.13 Using sex-specific
cut-off values for PMA (1561 mm2 in men, 1464 mm2 in
women), 22% of the patients were identified as sarcopenic
(below cut-off for PMA) with poorer survival,13 whereas in
our previous experience1 using SMI cut-offs (50 cm2/m2 in
men, 39 cm2/m2 in women), 50% of men and 33% of women
exhibited higher waitlist mortality associated with low SMI.
Therefore, comparison between studies is limited by diver-
gent outcomes, post-LT mortality in patients undergoing
LT12,13 vs. waitlist mortality in listed patients,1 which may
contribute to inconsistent results.
Abdominal total skeletal muscle and psoas muscle assess-
ment by CT images in patients with ESLD listed for LT is the
main strength of this multicentre study. Moreover, we
evaluated mortality risk by competitive risk analysis with LT
as the competitive event. Applying competing-risk analysis,
rather than conventional survival analysis, is a more robust
approach in the presence of competing event.38 Patients
were included from four North American LT centres with
standardized inclusion criteria to ensure homogeneous
patient population. We acknowledge limitations of the
present study, as we could not include patients without an
available CT for muscularity assessment. Also, we were
unable to evaluate muscle quality and muscle strength
because of the retrospective nature of the study.
Figure 3 Survival curves in (A) male and (B) female patients with high
and low psoas muscle index. Survival over time was estimated using
Kaplan–Meier curves, and the curves were compared using the log-rank
test. Longer survival was observed in patients with high psoas muscle in-
dex (PMI) compared with the patients with low PMI (log rank, P = 0.02
and P = 0.002 in men and women, respectively).
Table 6 Concordance between SMI and PMI categories
Male patients Female patients
Low SMI High SMI Low SMI High SMI
Low PMI 43 (34) 3 (3) 28 (72) 7 (10)
High PMI 83 (66) 117 (97) 11 (28) 61 (90)
Kappa coefficient
(95% CI)
0.31 0.63
0.22–0.41 0.47–0.77
P value <0.001 <0.001
CI, confidence interval; PMI, psoas muscle index; SMI, skeletal
muscle index.
Kappa coefficient was used to assess the agreement between two
assessments.
Low PMI was defined as PMI < 5.1 cm2/m2 in men and
PMI < 4.3 cm2/m2 in women.
Numbers in parentheses are percentages.
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In conclusion, CT-defined PMI cut-off predicts waitlist
mortality in patients with cirrhosis but identifies only an
incomplete subset of those at increased risk of mortality
indicated by low SMI. Therefore, we propose that SMI is a
more complete and robust measurement, especially in men
with cirrhosis, and given the poor performance of PMI, SMI
should not be substituted by PMI. Transferability of the
results to clinical settings requires consensus and more
specific definition of muscle abnormalities including both
muscle mass and quality in ESLD patients.
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